The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities

Affiliations

Editorial

Masato Yoneda et al. Hepatology. 2023.

. 2023 Oct 1;78(4):1020-1022.

doi: 10.1097/HEP.0000000000000478. Epub 2023 May 23.

¹ Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama, Japan.

No abstract available

Comment on

Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
Li J, Lu X, Zhu Z, Kalutkiewicz KJ, Mounajjed T, Therneau TM, Venkatesh SK, Sui Y, Glaser KJ, Hoodeshenas S, Manduca A, Shah VH, Ehman RL, Allen AM, Yin M. Li J, et al. Hepatology. 2023 Oct 1;78(4):1200-1208. doi: 10.1097/HEP.0000000000000417. Epub 2023 May 1. Hepatology. 2023. PMID: 37080558 Free PMC article. Clinical Trial.

1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
1. Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology. 2023;78:195–211.
1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017–1044.
1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel, Chair: EASL Governing Board representative: Panel members: EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75:659–689.
1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835.